AFP and neoplasm: There was a trend toward a better OS for males (11.0 months versus 8.0 months in females), Child–Pugh class A (10.0 months versus 4.0 months in Child–Pugh class B), AFP responders (13.0 months versus 9.0 months in AFP nonresponders), patients receiving higher dose of radiation (13.0 months versus 10.0 months in those receiving lower dose of radiation), patients undergoing IMRT combined with sorafenib (13.0 months versus 9.0 months in those without sorafenib), and overall responders (13.0 months versus 8.0 months in tumor nonresponders).